Kalshi to Allow Bets on FDA Reviews and Clinical Trials
The prediction market platform Kalshi is partnering with AppliedXL to allow investors to bet on the outcomes of late-stage clinical trials and FDA regulatory reviews. The pilot program initially includes contracts for experimental cancer drugs from Gilead and Summit Therapeutics.
X24 PerspectiveRelated Assets:
X24 Perspective